Our earlier work identified the signal transducer and activator of transcription 2 (STAT2) as a critical mediator in the promotion of type I interferon (IFN)-induced apoptosis. This is an interesting observation as IFNs are the only cytokines known to activate STAT2. Our most recent work has identified a sensitive conserved region in STAT2 that can determine cell fate following IFN stimulation. In our cell line model, in response to IFN-alpha treatment, a mutation introduced in the Src homology region 2 (SH2) domain of STAT2 made tumor cells undergo apoptosis only if they expressed the wild-type form of STAT2; otherwise the cells were only growth arrested by this cytokine. Based on our studies, we concluded that this single amino acid change prolonged the physical interaction between STAT1 and STAT2. This alone allowed the STAT heterodimer to increase its duration in the nucleus while increasing the transcriptional levels of IFN-stimulated genes. These findings prompted us to examine carefully one STAT2 single nucleotide polymorphism (SNP)detected in 12% in the human population. This SNP (M594I) is non-synonymous and is found in the SH2 domain of STAT2. We measured its transcriptional function and consequently type I IFN biological responses against wild-type STAT2. Our studies show that this SNP enhances the antiproliferative effects of type I IFNs. More interestingly, tumor cells that were known to be growth arrested by type IFNs, when they expressed this SNP became susceptible to the apoptotic effects of this cytokine. To establish an association between this SNP and IFN therapy, we analyzed a cohort of hepatitis C patients who had received IFN treatment to control viral infection. Patients heterozygote for STAT2 M594I responded better to IFN therapy than those who were STAT2 homozygote. Collectively, our findings strongly suggest that STAT2 is a critical component in the activation of apoptosis induced by type I IFNs and specific STAT2 mutations may be beneficial or counterproductive to a patient being treated with IFN.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Intramural Research (Z01)
Project #
1Z01BC010474-06
Application #
7733042
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
6
Fiscal Year
2008
Total Cost
$126,901
Indirect Cost
Name
National Cancer Institute Division of Basic Sciences
Department
Type
DUNS #
City
State
Country
United States
Zip Code
Maher, Stephen G; Sheikh, Faruk; Scarzello, Anthony J et al. (2008) IFN-alpha and IFN-lambda differ in their antiproliferative effects and duration of JAK/STAT signaling activity. Cancer Biol Ther 7:nihpa47781
Scarzello, Anthony J; Romero-Weaver, Ana L; Maher, Stephen G et al. (2007) A Mutation in the SH2 domain of STAT2 prolongs tyrosine phosphorylation of STAT1 and promotes type I IFN-induced apoptosis. Mol Biol Cell 18:2455-62
Gamero, Ana M; Potla, Ramesh; Sakamoto, Shuji et al. (2006) Type I interferons activate apoptosis in a Jurkat cell variant by caspase-dependent and independent mechanisms. Cell Signal 18:1299-308